Liraglutide and Semaglutide
Records checked
Compiled and citation-checked by GLP-1 Receptor Agonists editorial desk
Qualified clinical review None on record
Liraglutide and Semaglutide are curated as a pair under Incretin receptor agonists. This page reads them across four axes at once: what each one is recorded as binding, what the molecule is, what shape its indexed record set has, and what the application register returned. Every cell is either a sourced value or a count of records.
A larger record count is not a better compound. Counts track how long a compound has been studied and how heavily it has been indexed, nothing else. Nothing on this page ranks the two.
Identity and target
| Axis | Liraglutide | Semaglutide |
|---|---|---|
| Class as recorded | Incretin receptor agonists | Incretin receptor agonists |
| Receptor targets as recorded | GLP-1 receptor | GLP-1 receptor |
| Molecular formula | C172H265N43O51[4] | C187H291N45O59[10] |
| Molecular weight | 3751 g/mol[4] | 4114 g/mol[10] |
| CAS registry number | 204656-20-2[4] | 910463-68-2[10] |
| Reported half-life | Unknown No pharmacokinetics source was retrieved in v1. PubChem does not carry half-life as a property, so this is recorded as not yet sourced rather than estimated. | Unknown No pharmacokinetics source was retrieved in v1. PubChem does not carry half-life as a property, so this is recorded as not yet sourced rather than estimated. |
| Applications on the register | 11 on the query date[5] | 1 on the query date[11] |
Shape of the indexed record set
| Axis | Liraglutide | Semaglutide |
|---|---|---|
| Records indexed here | 12 | 12 |
| Phase 3 records | 4 | 3 |
| Phase 2 records | 1 | 1 |
| Phase 1 records | 0 | 0 |
| Trial records with no phase assigned | 2 | 3 |
| Review or synthesis records | 0 | 0 |
| Records that are not registered trials | 5 | 5 |
| Study models as assigned | human trial 11; rodent 1 | human trial 10; other 2 |
| Publication years covered | 2017–2022 | 2024–2025 |
| Derived record-set tier | Human trial evidence | Human trial evidence |
| Basis of that tier | 11 of 12 indexed records are interventional human trials by their own assigned publication type | 10 of 12 indexed records are interventional human trials by their own assigned publication type |
| Review state | Pending qualified review | Pending qualified review |
The derived tier counts record types. It is not an assessment of clinical efficacy, of safety, of study quality or of consensus, and the two tiers on this row are not a verdict about which compound is better supported.
Endpoint coverage, side by side
| Axis | Liraglutide | Semaglutide |
|---|---|---|
| Body weight and adiposity | 7 | 7 |
| Glycaemic control | 11 | 5 |
| Cardiovascular | 2 | 6 |
| Renal | 1 | 2 |
| Hepatic | 0 | 1 |
| Neurological | 0 | 0 |
Each endpoint is defined by a fixed set of subject headings, printed in full on the endpoint pages.
Which axes diverge
12 of the 23 axes above differ between the two, 10 carry the same value, and 1 are unsourced on both sides. A divergence is a difference in what the corpus records, not a difference in what either compound does.
| Result | Axes |
|---|---|
| Differ | Molecular formula; Molecular weight; CAS registry number; Applications on the register; Phase 3 records; Unphased trial records; Study models; Publication years; Glycaemic control records; Cardiovascular records; Renal records; Hepatic records |
| Same value | Class as recorded; Receptor targets; Records indexed; Phase 2 records; Phase 1 records; Review records; Non-trial records; Derived record-set tier; Body weight and adiposity records; Neurological records |
| Unsourced on both sides | Reported half-life |
The corpus also carries a curated divergence note for this pair, written for the reference layer rather than for this one. It is not reproduced here; the records behind it are cited[1, 2, 3] and listed in the sources below.
Records indexed under both
No record in this corpus is indexed under both compounds. That is the absence of a retrieved head-to-head record in this selection, not evidence that none exists.
Where this page sits
- Liraglutide: the full indexed record set
- Semaglutide: the full indexed record set
- Every curated pair in this class
Sources
- Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis. BMJ (2024). pmid:38286487
- Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet (2009). pmid:19515413
- A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. N Engl J Med (2015). pmid:26132939
- PubChem Compound Summary for CID 16134956, Liraglutide. PubChem, National Library of Medicine (2026). pubchem:16134956
- Drugs@FDA application register query for this compound, 11 application(s) returned: ANDA214568, ANDA217063, ANDA215421, NDA022341, ANDA217590. U.S. Food and Drug Administration, openFDA drugsfda endpoint (2026). fda:liraglutide
- Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med (2016). pmid:27295427
- Liraglutide and Renal Outcomes in Type 2 Diabetes. N Engl J Med (2017). pmid:28854085
- Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet (2016). pmid:26608256
- Glucagon-like peptide-1 receptor: mechanisms and advances in therapy. Signal Transduct Target Ther (2024). pmid:39289339
- PubChem Compound Summary for CID 56843331, Semaglutide. PubChem, National Library of Medicine (2026). pubchem:56843331
- Drugs@FDA application register query for this compound, 1 application(s) returned: NDA213051. U.S. Food and Drug Administration, openFDA drugsfda endpoint (2026). fda:semaglutide
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med (2016). pmid:27633186
- Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med (2021). pmid:33567185
- Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med (2023). pmid:37952131
- A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis. N Engl J Med (2021). pmid:33185364
- Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. N Engl J Med (2024). pmid:38785209
- Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med (2021). pmid:34170647